The updated Phase 1 data are consistent with prior disclosures and reinforce cemsidomide's potential, but the stock may have already priced in these results given prior data releases. Watch for Phase 2 MOMENTUM trial enrollment updates and the educational webinar on June 18, 2026 for further catalysts. The combination trial with elranatamab could expand the addressable population if positive.
Price Chart
Executive Summary
C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines). Responses deepened over time, with MRD negativity achieved in two patients. The data reinforce cemsidomide's differentiated safety profile and support its development as a potential best-in-class IKZF1/3 degrader, though the stock may have limited upside given prior data disclosures and the early-stage nature of the program.
Key Facts
- 53% ORR at 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines)
- 75% of patients received prior BCMA therapy and prior CAR-T or T-cell engager therapy
- Responses deepened over time: one patient at 100 µg deepened from PR to sCR, another from PR to VGPR
- MRD negativity achieved in two patients at 100 µg who achieved sCR and CR
- Median duration of response 7.9 months across all doses; 7 patients remain on treatment
- No discontinuations deemed related to cemsidomide; minimal dose reductions (5 patients, 7%)
- Phase 2 MOMENTUM trial (NCT07284758) is enrolling ~100 patients with ≥3 prior regimens
- Phase 1b combination trial with elranatamab (BCMAxCD3 bispecific) is ongoing
Financial Impact
No financial data provided; clinical-stage biotech with no approved products or revenue
Risk Factors
- Phase 2 MOMENTUM trial may not replicate Phase 1 ORR or durability
- Competition from other next-generation IKZF1/3 degraders and approved therapies
- Cemsidomide is investigational; regulatory approval is uncertain and years away
- Company has no approved products and relies on external financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310320 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.03 (−29.07%) |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.03 (−29.07%) |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | $3.03 (−16.44%) |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $3.03 (−21.83%) |
May 15, 2026 19w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $3.03 (−6.06%) |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.03 (−4.57%) |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.03 (−4.57%) |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $3.03 (+6.89%) |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $3.03 (+6.89%) |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | $3.03 (+12.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access